Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 622-625

  Nigam, Rishi ^a   Levitt, Jacob ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; AMENORRHEA; ANAPHYLAXIS; APLASIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE SKIN DISEASE; BK VIRUS INFECTION; BLISTER; BRONCHIOLITIS OBLITERANS; BULLOUS PEMPHIGOID; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CRYOGLOBULINEMIA; CUSHING SYNDROME; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEVER; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DYSPLASIA; HEADACHE; HEART FAILURE; HEART PALPITATION; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HOARSENESS; HUMAN; HYPERSENSITIVITY; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPHADENOPATHY; LYMPHOMA; MICROSCOPIC POLYANGIITIS; MULTIPLE ORGAN FAILURE; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PANCREATITIS; PANCYTOPENIA; PEMPHIGUS VULGARIS; PSYCHOSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRUS ACTIVATION; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PEMPHIGOID, BULLOUS; PREDNISONE;

EID: 84860908600     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64(5):903-908.
2. Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28(3):337-343.
3. Allen KJ, Wolverton SE. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports. J Drugs Dermatol. 2007;6(9):883-889.
4. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552. (Pubitemid 47236279)
5. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients. J Am Acad Dermatol. 2011 Jun 2 [Epub ahead of print]
6. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatol Treat. 2007;18(3):178-183. (Pubitemid 46854827)
7. Peterson JD, Chan LS. Effectiveness and side effects of anti- CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag. 2009;5(1):1-7.
8. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, et al. Rituximab for Patients With Refractory Mucous Membrane Pemphigoid. Arch Dermatol. 2011 Mar 21. [Epub ahead of print]
9. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-2466.
10. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62(12):1787-1795.
11. Gürcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother. 2007;41(10):1604-1610. (Pubitemid 47479788)
12. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595-603.
13. Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An 'nof- 1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol. 2009;160(5):1098-1102.
14. Sheehan DJ, Lesher JL Jr. Deep venous thrombosis after highdose intravenous immunoglobulin in the treatment of pemphigus vulgaris. Cutis. 2004;73(6):403-406. Review. (Pubitemid 38834469)
15. Mimouni D, Anhalt GJ. Pemphigus. Dermatol Ther. 2002;15: 362-368. (Pubitemid 36133864)
16. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772-1779. (Pubitemid 44631360)
17. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Jun 2. [Epub ahead of print]
18. Grundmann-Kollmann M, Kaskel P, Leiter U, Krähn G, Behrens S, Peter RU, et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol. 1999;135(6):724-725. (Pubitemid 29277853)
19. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137(7):870-873. (Pubitemid 32641646)
20. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041-2048.
21. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid - a 4 year follow-up. Br J Dermatol. 1974;91(1):103-109.
22. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447-1454. (Pubitemid 44790638)
23. Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8(2):85-92. (Pubitemid 46998551)
24. Stanbury RM, Graham EM. Systemic corticosteroid therapy - side effects and their management. Br J Ophthalmol. 1998 Jun;82(6):704-708. (Pubitemid 28306665)
25. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957-960. (Pubitemid 29268927)
26. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol. 1999;141(5):934.
27. Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (Cell- Cept) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003;7(3):193-197. (Pubitemid 36859095)
28. Epocrates Online Drugs [Internet]. San Mateo (CA): Epocrates, Inc. c2011. [continuously updated; cited 2011 Jul 5]. http://www.epocrates.com.